Bulletin
Investor Alert

press release

July 29, 2021, 7:16 a.m. EDT

23andMe to Report FY2022 First Quarter Financial Results

SUNNYVALE, Jul 29, 2021 (GLOBE NEWSWIRE via COMTEX) -- SUNNYVALE, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. /zigman2/quotes/222659849/composite ME +5.92% ("23andMe"), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 first quarter before the market opens on Friday, August 13, 2021. The company will webcast a conference call at 11:00 a.m. Eastern Time to discuss the quarter's financial results and report on business progress.

The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations . A webcast replay will be available at the same address for a limited time within 24 hours after the event.

About 23andMe
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company's mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world's largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com .

Forward-Looking Statements
This communication contains certain "forward-looking statements" including the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its crowdsourced research platform. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained herein are based on 23andMe's current expectations and beliefs concerning future developments and their potential effects, but there can be no assurance that these will be as anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Investor Relations Contact: investors@23andMe.com
Media Contact: press@23andMe.com

COMTEX_390602805/2471/2021-07-29T07:15:44

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/222659849/composite
US : U.S.: Nasdaq
$ 10.20
+0.57 +5.92%
Volume: 6.15M
Oct. 20, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$3.92 billion
Rev. per Employee
N/A
loading...

Partner Center

Link to MarketWatch's Slice.